<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118919</url>
  </required_header>
  <id_info>
    <org_study_id>AUCH-1</org_study_id>
    <nct_id>NCT05118919</nct_id>
  </id_info>
  <brief_title>A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis</brief_title>
  <official_title>A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGaia Pharma AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety, tolerability and preliminary&#xD;
      efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC)&#xD;
      patients as an oral administered local treatment in addition to Standard of Care (SoC)&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>The primary objective is to evaluate the safety and tolerability of BGP-014.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BGP-014</intervention_name>
    <description>Oral capsule containing lyophilised Lactobacillus reuteri</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has given written consent to participate in the study.&#xD;
&#xD;
          -  Diagnosed previously with UC (&gt; 6 months earlier) determined by clinical and&#xD;
             endoscopic histopathology (pathology showing chronic inflammatory changes). ≥1&#xD;
             documented previous flare-up and with last resolved flare &gt;3 months away.&#xD;
&#xD;
          -  Active UC determined by sigmoidoscopy before randomisation of study (baseline) and&#xD;
             defined as a total Mayo index score of 4 to 10 points (endoscopic subscore ≥1, rectal&#xD;
             bleeding ≥1).&#xD;
&#xD;
          -  Permitted concomitant SoC medications include: Oral aminosalicylates (5-ASA), with a&#xD;
             stable dose (1.6-4.8g/ day) for at least 12 days prior to screening, Visit 1. Steroids&#xD;
             (dose ≤15mg at screening, Visit 1) with further tapering of dose in accordance with&#xD;
             SoC until steroid tx termination. Immunomodulator, as: 6-Mercaptopurine, Azathioprine,&#xD;
             Methotrexate (Stable dose for &gt; 12 weeks prior to screening, Visit 1).&#xD;
&#xD;
          -  Females of childbearing potential must use effective contraceptives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Involvement in any investigational drug or device study within 30 days prior to this&#xD;
             study&#xD;
&#xD;
          2. Known intolerance of 5-ASA or sulphasalazine medications&#xD;
&#xD;
          3. Biologics or FMT treatment less than 12 weeks before screening&#xD;
&#xD;
          4. No 5-ASA or steroid topical treatment is allowed&#xD;
&#xD;
          5. Antibiotic treatment &lt; 1 month prior the study&#xD;
&#xD;
          6. Unable to maintain stable dose of NSAIDs and PPIs&#xD;
&#xD;
          7. Evidence of on-going extensive colitis&#xD;
&#xD;
          8. Fever, defined as a temperature of &gt;38.5 °C, at Visit 1&#xD;
&#xD;
          9. Anaemia, Hb value below 100&#xD;
&#xD;
         10. Evidence of on-going toxic megacolon&#xD;
&#xD;
         11. Presence of obstructive diseases of the gastrointestinal system&#xD;
&#xD;
         12. Any clinically significant concomitant disease that might interfere with patient&#xD;
             safety&#xD;
&#xD;
         13. Unwilling to withdraw probiotic supplements. Yoghurts without supplemented bacteria&#xD;
             are permitted&#xD;
&#xD;
         14. Pregnant&#xD;
&#xD;
         15. Planned abdominal surgery&#xD;
&#xD;
         16. Judged unable by the physician to comprehend information regarding the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per M Hellström, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra J Lierud</last_name>
    <phone>+46 8 724504400</phone>
    <email>petra.jones.lierud@biogaiapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology Department, Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Medical Sciences Gastroenterology and Hepatology, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

